OBJECTIVES: Tuberculosis (TB) remains a global health challenge, with current antibiotic therapies being limited by long treatments, side effects and multidrug-resistant mycobacterial strains. In addition, Mycobacterium tuberculosis (Mtb), the main causative agent of TB, employs evasion mechanisms particularly within alveolar macrophages being the primary host cells. Conventional therapies fail to modulate macrophage function or effectively target host immunity, which is crucial in TB pathogenesis. Emerging evidence points to induced pluripotent stem cell-derived macrophages (iMacs) with enhanced bactericidal activity as a promising cell-based approach for TB treatment. Therefore, this study aimed to compare iMacs with blood monocyte-derived macrophages (MDMs) in response to Bacillus Calmette-Guérin (BCG), the live attenuated TB vaccine and heat-killed Mtb (HKMT). METHODS: iMacs and MDMs were challenged with BCG and HKMT to assess their functional responses. Key parameters evaluated included cell migration, phagocytosis kinetics, levels of autophagy- and apoptosis-related proteins, and cytokine production profiles following infection. RESULTS: iMacs displayed enhanced migration, faster phagocytosis and increased expression of autophagy- and apoptosis-related proteins compared with MDMs. Moreover, iMacs showed a stronger pro-inflammatory cytokine response and rapid return to baseline cytokine levels post-infection. CONCLUSION: These findings support the potential of iMacs as an immunocompetent model for studying mycobacterial infections and as a tool for cell-based TB immunotherapies.
Immune activation and response dynamics of human iPSC-derived macrophages in tuberculosis infection models.
阅读:4
作者:Paasch Daniela, Schevel Hannah, Riehle Andrea, Costa Bibiana, Toufaili Hassan, Gehnen Tabea, Dahlmann Julia, Pavlou Andreas, Neehus Anna-Lena, Nguyen Ariane Hai Ha, Schiering Erika, Buchegger Theresa, Bustamante Jacinta, Hansen Gesine, Kalinke Ulrich, Gulbins Erich, Grassmé Heike, Lachmann Nico
| 期刊: | Clinical & Translational Immunology | 影响因子: | 3.800 |
| 时间: | 2026 | 起止号: | 2026 Jan 13; 15(1):e70071 |
| doi: | 10.1002/cti2.70071 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
